89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Memorial Sloan Kettering Cancer Center (MSK)

Status: Completed

Conditions: Glioblastoma

Treatments: Other: Blood draw; Device: MRI; Drug: 89Zr-J591; Device: PET/CT Scan

Study type: Interventional

Funder types: Other

Identifiers

NCT02410577

15-002

Details and patient eligibility

About

The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.

Enrollment: 2 patients

Sex: All

Ages: 26 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient age > 25 years old and < 80 years old
• Patients with reoccurrence of brain tumor
• The principal investigator or co-PI must review MRI and CT findings based on the radiologic assessment provided they meet the following imaging criteria (as established in the clinical trial 09-177):

OR

• Patients with newly diagnosed GBM and one of the following options:
• Eligible for surgery after the last research scan.
• Significant residual disease after initial surgery
• The principal investigator or co-PI must review MRI and CT findings and agree with the presence of significant residual disease
• Treatment (non-surgical) naïve
• Karnofsky Performance Score ≥ 70

Exclusion criteria

• Laboratory values:

  • Serum creatinine >2.5 mg/dL.
  • AST (SGOT) >2.5x ULN.
  • Bilirubin (total) >1.5x ULN.
  • Serum calcium >11 mg/dL.

• Pregnant or breastfeeding (if a female is of childbearing potential, and unsure of pregnancy status, a standard pregnancy test should be done).

• If an initial biopsy demonstrates neoplasm other than GBM

• Presence of any other co-existing condition which, in the judgment of the investigator, might increase the risk to the subject.

• Presence of serious systemic illness, including: uncontrolled inter-current infection, uncontrolled malignancy, significant renal disease, or psychiatric/social situations, which might limit compliance with study requirements

• Prior treatment.

• Other serious illness (es), which might preclude completion of this, study or interfere with determination of causality of any adverse effects experienced in this study.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2 participants in 1 patient group

89Zr-J591

Experimental group

Description:

Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.

Treatment:

Other: Blood draw

Device: MRI

Device: PET/CT Scan

Drug: 89Zr-J591